Aerie licenses DSM's bioerodible implant technology for ophthalmic use for $15M

Aerie Pharmaceuticals licensed DSM's bioerodible implant technology for ophthalmic applications in a deal valued at $15 million.

“Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million”market-scope.com

• 1 source
• market-scope.comAerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million | Market ScopeJon SwedienAug 3, 2018

Summarized from public sources; check the original articles before acting on it.